Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Ascendis Pharma ADR (ASND)

Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,336,511
  • Shares Outstanding, K 58,224
  • Annual Sales, $ 288,670 K
  • Annual Income, $ -521,070 K
  • 60-Month Beta 0.50
  • Price/Sales 29.27
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ASND with:

Options Overview Details

View History
  • Implied Volatility 98.27% ( +2.71%)
  • Historical Volatility 30.24%
  • IV Percentile 97%
  • IV Rank 76.22%
  • IV High 118.25% on 04/17/24
  • IV Low 34.25% on 09/15/23
  • Put/Call Vol Ratio 84.90
  • Today's Volume 1,804
  • Volume Avg (30-Day) 625
  • Put/Call OI Ratio 1.27
  • Today's Open Interest 11,782
  • Open Int (30-Day) 10,552

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.57
  • Number of Estimates 7
  • High Estimate -1.00
  • Low Estimate -1.94
  • Prior Year -2.12
  • Growth Rate Est. (year over year) +25.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
136.19 +0.54%
on 04/25/24
156.84 -12.69%
on 04/10/24
-7.53 (-5.21%)
since 03/25/24
3-Month
127.95 +7.02%
on 01/31/24
161.00 -14.95%
on 02/26/24
+5.18 (+3.93%)
since 01/25/24
52-Week
66.03 +107.38%
on 04/28/23
161.00 -14.95%
on 02/26/24
+58.57 (+74.74%)
since 04/25/23

Most Recent Stories

More News
Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders

/CNW/ - Ascendant Resources Inc. (TSX: ASND) (OTCQB: ASND) ("Ascendant" or the "Company") is pleased to announce the voting results of the Company's 2023...

ASND : 136.93 (-4.37%)
ASND.TO : 0.0600 (+9.09%)
Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders

/PRNewswire/ - Ascendant Resources Inc. (TSX: ASND) (OTCQB: ASND) ("Ascendant" or the "Company") is pleased to announce the voting results of the Company's...

ASND.TO : 0.0600 (+9.09%)
ASND : 136.93 (-4.37%)
Why Shares of Ascendis Pharma Are Climbing Monday

A critical response letter from the FDA means hope remains for the company's hyperthyroidism therapy candidate.

ASND : 136.93 (-4.37%)
ASCENDIS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ascendis To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ascendis Pharma ("Ascendis" or the...

ASND : 136.93 (-4.37%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ascendis Pharma A/S - ASND

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ascendis Pharma A/S ("Ascendis" or the "Company") (NASDAQ: ASND). Such...

ASND : 136.93 (-4.37%)
ROSEN, A TOP RANKED LAW FIRM, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation - ASND

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of...

ASND : 136.93 (-4.37%)
Ascendis Pharma A/S (ASND) Soars 8.5%: Is Further Upside Left in the Stock?

Ascendis Pharma A/S (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more...

ASND : 136.93 (-4.37%)
AMRN : 0.8601 (-2.11%)
ASND EQUITY NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation - ASND

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of...

ASND : 136.93 (-4.37%)
ASCENDIS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ascendis To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ascendis Pharma ("Ascendis" or the...

ASND : 136.93 (-4.37%)
ASCENDIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Ascendis Pharma A/S on Behalf of Ascendis Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Ascendis Pharma A/S (“Ascendis” or the “Company”) (NASDAQ: ASND) on behalf...

ASND : 136.93 (-4.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology,...

See More

Key Turning Points

3rd Resistance Point 151.44
2nd Resistance Point 148.92
1st Resistance Point 146.05
Last Price 136.93
1st Support Level 140.66
2nd Support Level 138.14
3rd Support Level 135.27

See More

52-Week High 161.00
Last Price 136.93
Fibonacci 61.8% 124.72
Fibonacci 50% 113.51
Fibonacci 38.2% 102.31
52-Week Low 66.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar